Hims & Hers Health is trading at €30.40, down 4.8% following a Q1 2026 revenue miss and cautious forward guidance.
- The company is facing intense regulatory scrutiny and legal challenges surrounding its weight-loss products and GLP-1 offerings.
- Investor sentiment remains under strain due to a softer outlook tied to shifting telehealth regulations and increasing competitive threats in the obesity care market.